• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. Reply.

作者信息

Salama Carlos, Mohan Shalini V

机构信息

Elmhurst Hospital Center-Icahn School of Medicine at Mount Sinai Hospital, New York, NY.

Genentech, South San Francisco, CA

出版信息

N Engl J Med. 2021 Apr 15;384(15):1473-1474. doi: 10.1056/NEJMc2100217. Epub 2021 Mar 3.

DOI:10.1056/NEJMc2100217
PMID:33657287
Abstract
摘要

相似文献

1
Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. Reply.托珠单抗用于新冠肺炎肺炎住院患者。回复。
N Engl J Med. 2021 Apr 15;384(15):1473-1474. doi: 10.1056/NEJMc2100217. Epub 2021 Mar 3.
2
Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. Reply.托珠单抗用于新冠肺炎肺炎住院患者。回复。
N Engl J Med. 2021 Apr 15;384(15):1474. doi: 10.1056/NEJMc2100217. Epub 2021 Mar 3.
3
Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia.托珠单抗治疗新冠病毒肺炎住院患者
N Engl J Med. 2021 Apr 15;384(15):1473. doi: 10.1056/NEJMc2100217. Epub 2021 Mar 3.
4
'Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM' - Author's reply.“在炎症标志物升高的住院COVID-19患者中早期使用托珠单抗；COVIDSTORM”——作者回复
Clin Microbiol Infect. 2022 Nov;28(11):1520-1521. doi: 10.1016/j.cmi.2022.06.028. Epub 2022 Jul 4.
5
Tocilizumab in patients hospitalized with COVID-19 pneumonia: systematic review and meta-analysis of randomized controlled trials.托珠单抗治疗 COVID-19 肺炎住院患者：随机对照试验的系统评价和荟萃分析。
J Investig Med. 2022 Jan;70(1):55-60. doi: 10.1136/jim-2021-002001. Epub 2021 Sep 24.
6
Impact of Timing of Tocilizumab Use in Hospitalized Patients With SARS-CoV-2 Infection.托珠单抗使用时机对住院的2019冠状病毒病感染患者的影响
Respir Care. 2022 May;67(5):629-630. doi: 10.4187/respcare.10067.
7
Reply: Low-Dose Tocilizumab With High-Dose Corticosteroids in Patients Hospitalized for COVID-19 Hypoxic Respiratory Failure Improves Mortality Without Increased Infection Risk.回复：对于因 COVID-19 低氧性呼吸衰竭住院的患者，低剂量托珠单抗联合高剂量皮质类固醇可改善死亡率且不增加感染风险。
Ann Pharmacother. 2022 Apr;56(4):507-508. doi: 10.1177/10600280211036047. Epub 2021 Jul 30.
8
Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.托珠单抗与标准治疗对 COVID-19 肺炎住院患者临床恶化的影响：一项随机临床试验。
JAMA Intern Med. 2021 Jan 1;181(1):24-31. doi: 10.1001/jamainternmed.2020.6615.
9
Tocilizumab in Treatment for Patients With COVID-19-Reply.托珠单抗治疗新型冠状病毒肺炎患者的回复
JAMA Intern Med. 2021 Jul 1;181(7):1019-1020. doi: 10.1001/jamainternmed.2021.0404.
10
Tocilizumab in Treatment for Patients With COVID-19-Reply.托珠单抗用于治疗新型冠状病毒肺炎患者的回复
JAMA Intern Med. 2021 Jul 1;181(7):1020-1021. doi: 10.1001/jamainternmed.2021.0407.

引用本文的文献

1
Temporal Dynamics of Host Immune Response Associated With Disease Severity and Time to Recovery in Patients Hospitalized for COVID-19.与COVID-19住院患者疾病严重程度和恢复时间相关的宿主免疫反应的时间动态变化
Crit Care Explor. 2022 Sep 7;4(9):e0760. doi: 10.1097/CCE.0000000000000760. eCollection 2022 Sep.
2
Gp130-HIF1α axis-induced vascular damage is prevented by the short-term inhibition of IL-6 receptor signaling.IL-6 受体信号短期抑制可预防 gp130-HIF1α 轴诱导的血管损伤。
Proc Natl Acad Sci U S A. 2024 Jan 9;121(2):e2315898120. doi: 10.1073/pnas.2315898120. Epub 2024 Jan 2.
3
Does tocilizumab have an effect on the clinical outcomes in COVID-19 patients? A meta-analysis of randomized control trials.
托珠单抗对COVID-19患者的临床结局有影响吗？一项随机对照试验的荟萃分析。
J Pharm Policy Pract. 2023 Nov 20;16(1):151. doi: 10.1186/s40545-023-00662-w.
4
What is the aetiology of dysnatraemia in COVID-19 and how is this related to outcomes in patients admitted during earlier and later COVID-19 waves? A multicentre, retrospective observational study in 11 Dutch hospitals.在 COVID-19 中，电解质紊乱的病因是什么，以及这与在 COVID-19 早期和晚期波次入院的患者结局有何关联？11 家荷兰医院的一项多中心、回顾性观察性研究。
BMJ Open. 2023 Nov 14;13(11):e075232. doi: 10.1136/bmjopen-2023-075232.
5
Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story.JAKinib 的选择性、疗效和安全性：一个仍在不断发展的故事的新证据。
Ann Rheum Dis. 2024 Jan 11;83(2):139-160. doi: 10.1136/ard-2023-223850.
6
Immunophenotypes of anti-SARS-CoV-2 responses associated with fatal COVID-19.与致命性新冠肺炎相关的抗SARS-CoV-2反应的免疫表型
ERJ Open Res. 2022 Dec 5;8(4). doi: 10.1183/23120541.00216-2022. eCollection 2022 Oct.
7
Efficacy and safety of baricitinib and tocilizumab in hospitalized patients with COVID-19: A comparison using systematic review and meta-analysis.巴瑞替尼和托珠单抗治疗新冠住院患者的疗效与安全性：一项基于系统评价和荟萃分析的比较
Front Pharmacol. 2022 Oct 14;13:1004308. doi: 10.3389/fphar.2022.1004308. eCollection 2022.
8
COVID-19 and Adult Acute Leukemia: Our Knowledge in Progress.新型冠状病毒肺炎与成人急性白血病：我们的研究进展
Cancers (Basel). 2022 Jul 29;14(15):3711. doi: 10.3390/cancers14153711.
9
Drug Repurposing for COVID-19: A Review and a Novel Strategy to Identify New Targets and Potential Drug Candidates.新冠病毒药物再利用：综述及一种新的识别新靶点和潜在药物候选物的策略。
Molecules. 2022 Apr 23;27(9):2723. doi: 10.3390/molecules27092723.
10
Characteristics and Outcomes of Patients With Frailty Admitted to ICU With Coronavirus Disease 2019: An Individual Patient Data Meta-Analysis.2019年冠状病毒病入住重症监护病房的衰弱患者的特征与结局：一项个体患者数据荟萃分析
Crit Care Explor. 2022 Jan 18;4(1):e0616. doi: 10.1097/CCE.0000000000000616. eCollection 2022 Jan.